Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) FCF Margin: 2021-2022

Historic FCF Margin for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to 12.81%.

  • Cardiol Therapeutics' FCF Margin fell 5002.00% to 12.81% in Q3 2022 from the same period last year, while for Sep 2022 it was 41.42%, marking a year-over-year change of. This contributed to the annual value of -29,904.22% for FY2021, which is 2994854.00% down from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' FCF Margin is 12.81%, which was down 53.92% from 27.80% recorded in Q2 2022.
  • Cardiol Therapeutics' FCF Margin's 5-year high stood at 106.40% during Q1 2022, with a 5-year trough of 12.81% in Q3 2022.
  • Moreover, its 2-year median value for FCF Margin was 62.83% (2021), whereas its average is 59.11%.
  • Examining YoY changes over the last 5 years, Cardiol Therapeutics' FCF Margin showed a top increase of 2,751bps in 2022 and a maximum decrease of 6,675bps in 2022.
  • Quarterly analysis of 2 years shows Cardiol Therapeutics' FCF Margin stood at 30.51% in 2021, then slumped by 5,002bps to 12.81% in 2022.
  • Its last three reported values are 12.81% in Q3 2022, 27.80% for Q2 2022, and 106.40% during Q1 2022.